Loading…
Lobbying Spend
$6.1M
Filings
96
Firms Hired
3
Active Period
2014–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Drug Shortage Compounding Patient Access Act of 2025
2026 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: —
Matched citations: H.R. 5316
SAFE Drugs Act of 2025
2026 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: —
Matched citations: H.R. 6509
CLEAR LABELS Act
2026 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: —
Matched citations: H.R. 8269
CLEAR LABELS Act
2026 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: —
Matched citations: S. 3788
SAFE Drugs Act of 2026
2026 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: —
Matched citations: S. 3794
Drug Shortage Compounding Patient Access Act of 2025
2026 · second_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 5316
SAFE Drugs Act of 2025
2026 · second_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 6509
CLEAR LABELS Act
2026 · second_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 8269
CLEAR LABELS Act
2026 · second_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: S. 3788
SAFE Drugs Act of 2026
2026 · second_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: S. 3794
Drug Shortage Compounding Patient Access Act of 2025
2026 · first_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 5316
SAFE Drugs Act of 2025
2026 · first_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: H.R. 6509
CLEAR LABELS Act
2026 · first_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: S. 3788
SAFE Drugs Act of 2026
2026 · first_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Client expense: $220,000 · Firm income: —
Matched citations: S. 3794
Drug Shortage Compounding Patient Access Act of 2025
2025 · fourth_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 5316
Drug Shortage Compounding Patient Access Act of 2025
2025 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 5316
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
2025 · first_quarter · Firm: THORN RUN PARTNERS
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R.167
Drug Origin Transparency Act of 2023
2025 · first_quarter · Firm: THORN RUN PARTNERS
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R.3810
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
2024 · fourth_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 167
Drug Origin Transparency Act of 2023
2024 · fourth_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3810
Drug Origin Transparency Act of 2023
2024 · fourth_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3810
Safer Compounding in Hospitals Act of 2024
2024 · fourth_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 8749
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
2024 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.167
Drug Origin Transparency Act of 2023
2024 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.3810
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
2024 · third_quarter · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Client expense: $120,000 · Firm income: —
Matched citations: H.R. 167
Source: Senate LDA